Cyclacel Pharmaceuticals, Inc. (CYCC) is one of Tuesday’s notable stocks in decline, down 64% to $1.03. The plunge comes after the company announced enrollment of 486 patients, continuation to final analysis and recommendations of the independent Data and Safety Monitoring Board [DSMB] of the company’s Phase 3 SEAMLESS study. However, DSMB said the planned futility […] View the full post at: Morning Buzz: Cyclacel Pharmaceuticals, Inc. (CYCC), Salix Pharmaceuticals Ltd. (SLXP), Microsoft (MSFT), Apple Inc. (AAPL), SolarCity (SCTY) Related posts: Microsoft talking to Facebook for a possible deal Microsoft Loses Top Executive To Juniper Yahoo – Google Deal To Be Investigated